Running Head: TUMOR CONFERENCE: TESTICULAR CANCER

Tumor Conference:
Testicular Cancer
Rachel LeSage
Argosy University Twin Cities
Julie Yasgar

Running Head: TUMOR CONFERENCE: TESTICULAR CANCER

On Wednesday, January 27, I attended the Tumor conference at
the Baton Rouge General. The case that I found to be the most
interesting was a 32 year old male presenting with right testicular
cancer.
He first presented with an enlarged abnormal right testicle. He
was first given antibiotics and Mobic and had no improvement. An
ultrasound showed a 6.7-centimeter mass. He then underwent an
orchiectomy and presented with seminoma confined to the testis with
flared margins and was considered a stage II due to the enlarged
adenopathy.
Post surgical Computed Tomography (CT) scan was taken to
confirm the extent of nodal involvement. If the para-aortic nodes are
involved, this patient will be treated with external beam radiation
therapy from his 10th thoracic spine down to his right pelvis, with his
left testicle in a clam shell to prevent sterility. The administration of
chemotherapy was also recommended. Etopisode, Ifosfamide, and
Cisplatin were all mentioned. Chemotherapy will be administered
regardless of lymph involvement.
Recurrence rates were discussed when determining modality of
treatment. There is a 15-20% chance of recurrence with chemotherapy
treatment alone, and is reduced to only 5% recurrence with radiation
therapy and chemotherapy treatments both administered.

Running Head: TUMOR CONFERENCE: TESTICULAR CANCER

The CT scan was reviewed at the conference and it was agreed
that the para-aortic lymph nodes were not enlarged enough on the
scan to assume involvement. The patient is not recommended to
receive radiation therapy treatment and will be advised to move
forward with chemotherapy treatment only.